Liyong Qin - China Evergrande Ex Director
| EVGRF Stock | USD 0.02 0.00 0.00% |
Insider
Liyong Qin is Ex Director of China Evergrande New
| Age | 45 |
| Web | https://health.evergrande.com |
China Evergrande Management Efficiency
The company has return on total asset (ROA) of (0.0282) % which means that it has lost $0.0282 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (3.145) %, meaning that it generated substantial loss on money invested by shareholders. China Evergrande's management efficiency ratios could be used to measure how well China Evergrande manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| MD JD | Acadia Healthcare | N/A | |
| Christopher Hunter | Acadia Healthcare | 56 | |
| Rusty Yeager | Encompass Health Corp | N/A | |
| Laurence Harrod | Acadia Healthcare | 67 | |
| Robin Doerr | InnovAge Holding Corp | 60 | |
| Gregory Carmichael | Encompass Health Corp | 59 | |
| John Gochnour | Pennant Group | 41 | |
| L Shaw | Encompass Health Corp | 75 | |
| BS MA | Enhabit | 56 | |
| Qing Pan | Concord Medical Services | 45 | |
| Kevin Connor | Encompass Health Corp | 53 | |
| Patricia Maryland | Encompass Health Corp | 67 | |
| LLM JD | ModivCare | 54 | |
| Ryan Kubota | InnovAge Holding Corp | N/A | |
| Liping Zhang | Concord Medical Services | 48 | |
| J Abernathy | National HealthCare | 83 | |
| Mark Miller | Encompass Health Corp | N/A | |
| RN MHA | InnovAge Holding Corp | 73 | |
| Kevin Ellich | ModivCare | N/A | |
| Heath Sampson | ModivCare | 53 | |
| Crissy Carlisle | Enhabit | 52 | |
Management Performance
| Return On Equity | -3.14 | |||
| Return On Asset | -0.0282 |
China Evergrande New Leadership Team
Elected by the shareholders, the China Evergrande's board of directors comprises two types of representatives: China Evergrande inside directors who are chosen from within the company, and outside directors, selected externally and held independent of China. The board's role is to monitor China Evergrande's management team and ensure that shareholders' interests are well served. China Evergrande's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, China Evergrande's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Yongzhuo Liu, Ex Chairman | ||
| Liyong Qin, Ex Director | ||
| Yifei Huang, Chief Officer | ||
| Shawn Siu, Ex Chairman | ||
| Suet Tso, Publisher Sunday | ||
| Darong Pan, Chief Officer | ||
| York Leung, Chief Beauty | ||
| Chi Cheung, Chief Beauty | ||
| Ka Pun, Chief Weekly | ||
| Shu Lui, Chief Digest |
China Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is China Evergrande a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -3.14 | |||
| Return On Asset | -0.0282 | |||
| Profit Margin | (0.55) % | |||
| Operating Margin | (0.36) % | |||
| Current Valuation | 8.22 B | |||
| Shares Outstanding | 10.84 B | |||
| Shares Owned By Insiders | 60.29 % | |||
| Shares Owned By Institutions | 0.02 % | |||
| Price To Book | 0.08 X | |||
| Price To Sales | 0.25 X |
Currently Active Assets on Macroaxis
Other Information on Investing in China Pink Sheet
China Evergrande financial ratios help investors to determine whether China Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in China with respect to the benefits of owning China Evergrande security.